Since 2021, Trethera has demonstrated remarkable growth of its team and an expanding list of potential disease indications and patents.
With FDA Orphan Drug Status for two diseases and a clear roadmap to commercialization, Trethera is well-positioned for both patient impact and investor value.
Successful Scientific Founders and Prize-Winning Visionaries
Our scientific founders and advisors have a proven track record, including discovery of the drugs Xtandi and Erleada, with combined annual sales exceeding $5 billion. They have also contributed to major milestones such as Kite’s $12 billion exit and Allogene’s $300 million IPO, while pioneering new drug class discoveries for MS and cancer therapies.
Trethera’s key advisors include recipients of prestigious scientific honors such as the Dystel, Charcot, and Lasker Prizes; business leaders from Jefferies Bank and Goldman Sachs; and leadership experience at Harvard, Stanford, UCLA, and the American Board of Toxicology.
Trethera’s board is comprised of leaders who have helped grow successful businesses like Agensys ($400M) and Halozyme ($4B). With deep industry expertise gained from roles at the Mayo Clinic, McKinsey & Company, and Medtronic, they bring company development experience to the table.
